Alexander Green claims to know the next Magnificent Seven stocks that could turn $11,000 into over a million in just 6 years. However, he won't reveal the stocks unless you purchase his newsletter. The good news is that he left enough clues in the presentation to figure out the

stocks, and I reveal them here for free. All I ask in return is that you drop a like and subscribe if you appreciate the effort I put into this. This is actually the second time I've covered this presentation from Green, and the original was my most viewed video of all time.

However, Green has made some changes, dropping two stocks from his original presentation and adding two new ones. The two stocks removed were biotech stocks Xenia and 10x Genomics. I'll reveal the two new stocks later in this video. Let's jump straight

into it and start revealing the stocks. Alexander Green claims this about the first stock: the AIC CPU developer that could be the next trillion-dollar company. This is Arm Holdings, and the ticker is ARMM. Arm Holdings is a British semiconductor and software design company specializing in designing

microprocessor architectures. Unlike traditional chip manufacturers, Arm licenses its designs to other companies such as Apple, Samsung, and Qualcomm, which then produce their own chips based on Arm's blueprints. Its energy-efficient designs are widely used in smartphones, tablets, and increasingly in data centers and IoT devices. Arm

plays a crucial role in the global tech ecosystem, acting as a cornerstone for modern computing. Green originally recommended this stock back in May, and since then, the stock is up a little over 30%, which is outpacing the market, which is up around 18%. I personally rate Arm a

hold and here's why. First, there's valuation concerns. Arm's valuation feels stretched especially after its IPO. The company trades at a premium due to its dominant position in chip architecture, but that premium leaves little room for error. Investors are paying a lot for future growth that may take years to

materialize. Second is slower smartphone market growth. A significant portion of Arm's revenue comes from smartphone related designs. With smartphone shipments plateauing globally, revenue growth from this segment is likely to slow, limiting Arm's upside in the near term. Third is reliance on key customers. Arm depends heavily on big players like

Apple, Samsung, and Qualcomm. While these relationships are strong, heavy reliance on a few customers can be risky. If any of them decide to reduce dependency on Arm's architecture, fourth is competition in AI and data centers. While Arm has made strides in diversifying into AI and data centers,

these markets are highly competitive with players like Nvidia and AMD dominating. Arm's ability to carve out a significant piece of this pie remains uncertain. Fifth is geopolitical risks. Arm's business is exposed to global supply chains and geopolitical tensions, particularly between the US and China. Any restrictions or disruptions could

impact their growth prospects. So, while Arm has a great technology portfolio and market position, there are enough risks and uncertainties to warrant a hold rating. Let's see how the company executes in these challenging areas before jumping in further. What do you think? Let me know in the comments. Here's

how Green describes the second company, the company reinventing the internet with AI. This stock is Cloudflare, and the ticker is NET. Cloudflare is a global network service provider that enhances the security, performance, and reliability of websites and applications. It offers services such as content delivery, DDoS

mitigation, DNS management, and web application firewalls acting as a reverse proxy between visitors and the origin server. Since May 2024, when the stock was originally pitched by Green Cloud, Cloudflare is up about 18%, which is exactly what the market is up.

I personally think Cloudflare is a buy, and here's why. First, Cloudflare has impressive financial growth. Cloudflare has consistently delivered strong financial results. In the third quarter, the company reported earnings per share of 20 cents, a 25% increase from the previous year, and revenue growth of 28%

to $43.1 million. This consistent growth underscores its solid financial health. Second, it's strategic positioning in AI and cryptocurrency. Cloudflare is strategically positioned in the booming AI and cryptocurrency sectors. The company provides secure links to services like OpenAI's ChatGPT and has

integrated Nvidia's AI infrastructure into its network, enhancing capabilities in these high-growth areas. Third, it's expanding customer base. The company's customer base is growing rapidly, particularly among large clients. Cloudflare's platform appeals to a wide range of developers building AI and

blockchain applications, leading to increased adoption among top startups. Fourth, it's strong market position and ratings. Cloudflare holds a strong IBD composite rating of 97 and a B-plus accumulation distribution rating, indicating robust institutional support and a solid market position. Fifth, it's

positive analyst outlook. Analysts are optimistic about Cloudflare's future. Oppenheimer maintained a buy rating with a price target of $110, reflecting confidence in the company's growth prospects. In summary, Cloudflare's strong financial performance, strategic positioning in emerging technologies, expanding customer

Based on solid market ratings and a positive analyst outlook, it makes a compelling buy. I'm going to reveal the rest of the green stock in about 20 seconds, but before I do that, I want to remind you to click the link in the description to check out Alpha Picks. I reviewed over 100 stocks

picking services and Alpha Picks performs the best and actually beats the market easily. And between November 18th to December 5th, this service is $140 off during its Black Friday sale. To take advantage of this awesome deal, just click the link in the description. Here's

how Green describes the third stock: the most exciting and predictable way to invest in AI. This stock is ASML, and the ticker is also ASML. It is one of the new additions Green made as it wasn't part of the original presentation. ASML is replacing

Exxon, which has seen a slight decline since May. ASML holding is a Dutch company specializing in photolithography machines for semiconductor production. It's the leading supplier of advanced systems, including exclusive extreme ultraviolet machines essential for creating microchips in modern

electronic devices. I personally think ASML is a borderline buy, and here's why. First reason why is ASML's dominance in EUV technology. ASML is the sole manufacturer of extreme ultraviolet lithography machines essential for producing advanced semiconductors. This monopoly positions

ASML as a critical player in the semiconductor supply chain. Second is strong long-term growth projections. Despite recent market fluctuations, ASML has reaffirmed its 2030 revenue target of 44 billion EUR to 60 billion EUR with a gross

margin between 56% and 60%. This optimistic outlook underscores the company's confidence in sustained growth. Third is exposure to AI-driven demand. The surge in artificial intelligence applications is boosting demand for advanced chips, as ASML's cutting-edge lithography machines are crucial for manufacturing these chips.

aligning the company with the AI industry's expansion. Fourth is robust financial performance. ASML reported 7.5 billion EUR in net sales and €2.1 billion EUR in net income for Q3 2024, reflecting strong financial health and operational efficiency. This solid

performance provides a stable foundation for future growth. Fifth is recent stock volatility. The stock has experienced significant volatility, including a 16% drop following a lowered 2025 sales forecast. This presents both risks and potential buying opportunities for investors willing to navigate the uncertainty. In summary, ASML's unique

market position and growth prospects make it a compelling consideration. However, investors should weigh these strengths against the current challenges and market volatility. This is what Green says about the fourth stock: the most powerful generative AI software company in the world. This stock is Palantir, and the ticker is

PLTR. It is the second new member of The Magnificent 7 and replaces 10x Genomics. 10x Genomics is down about 50% since May, which is likely why Green decided to drop it. Palantir is an American software company specializing in big data

analytics, founded in 2003 by Peter Thiel, Steven Cohen, Alex Karp, and Joe Lonsdale. The company develops platforms like Palantir Gotham and Palantir Foundry, which are utilized by government agencies and commercial enterprises for data integration and analysis. I personally

I think Palantir is a hold or borderline sell, and here's why. First issue is its Sky-high valuation. Palantir stock has soared over 250% this year, leading to a forward price-to-sales ratio of around 26. This premium valuation suggests that the

stock price already reflects significant future growth, making it potentially overvalued at current levels. Second is Insider selling concerns. Recent reports indicate that key executives, including CEO Alex Karp, have sold substantial shares. Such Insider selling can be a red flag, signaling that those closest to the

company might believe the stock has peaked. Third is slowing revenue growth. While Palantir reported a 30% revenue increase in Q3, this growth rate has decelerated compared to previous quarters. Slowing growth could indicate challenges in maintaining the company's

rapid expansion. Fourth is analyst skepticism. Several analysts have downgraded Palantir, citing concerns over its unsustainable valuation. Jefferies analyst Brent Thill, for instance, downgraded the stock due to its high revenue multiple compared to other software companies. Lastly is market volatility. Palantir

stock has experienced significant volatility, with numerous instances of price swings exceeding 5% in a single day. Such unpredictability can pose risks for investors, especially those with lower risk tolerance. In summary, while Palantir has shown impressive growth, these factors suggest caution. Here's what

Green says about the fifth stock. AI robots revolutionizing manufacturing. This is Symbotic, and the ticker is SYM. Symbotic specializes in automating warehouse operations using advanced robotics and artificial intelligence. The company designs and implements systems that improve efficiency, accuracy, and scalability in logistics and supply

Chain management is making warehouses smarter and more cost-effective. The stock crashed about 50% in late July due to a forecast of current quarter revenue and adjusted core profit falling short of estimates, attributed to increased costs and a slowdown in the deployment of its warehouse automation systems.

However, the stock has clawed back to break even and surged 27% in mid-November after Symbotic reported its fiscal fourth quarter results, achieving revenue of $577 million and net income of $28 million, marking its first profitable quarter as a public company. I personally think

Symbotic is a hold, and here's why. First, there's profitability concerns. Despite impressive revenue growth, Symbotic has yet to achieve consistent profitability. The company reported a net loss of $50.6 million for the fiscal year, an improvement from the previous year's

loss, but still a concern for investors seeking stable earnings. Second, there's customer concentration risk. A significant portion of Symbotic's revenue comes from a limited number of large clients, notably Walmart. This heavy reliance means that any changes in these clients' business strategies or financial health could substantially impact

Symbotic's financial performance. Third, there's a competitive landscape. The warehouse automation industry is becoming increasingly competitive, with numerous players offering similar solutions. Symbotic faces the challenge of differentiating itself and maintaining its market share amidst this growing competition. Fourth is implementation

challenges. Deploying Symbotic automation systems is a complex and time-consuming process, often taking up to two years per site. This lengthy implementation period can delay revenue recognition and poses a risk if clients decide to cancel or postpone projects. Fifth is market volatility. Symbotic's stock has

experienced significant volatility with shares down nearly 30% year-to-date despite recent gains. This fluctuation can be unsettling for investors seeking stable returns and may indicate underlying market concerns. In summary, while Symbotic has shown promising growth and innovation, these factors suggest that it may not be

the optimal investment choice at this time. As always, conduct thorough research and consider your financial goals before making any investment decisions. Here's how Green describes the six stock the company protecting us from the dangers of AI. This stock is CyberArk, and the ticker is CYBR. CyberArk is a global leader in

identity security, specializing in protecting organizations from cyber threats by securing privileged access across on-premises, cloud, and hybrid environments. Founded in 1999, the company offers a comprehensive suite of solutions including privileged access management, endpoint privileged security, and secrets management to safeguard critical assets and data. CyberArk has

performed very well since Green recommended it back in May. Since then, it's up around 38%. I personally think CyberArk is a buy, and here's why. First is their stellar Q3 performance. In the third quarter of 2024, CyberArk reported

earnings per share of $0.94, significantly surpassing analyst expectations of $0.46. This robust performance underscores the company's strong operational execution and market demand for its cybersecurity solutions. Second is accelerating revenue growth. CyberArk's revenue has been on

an upward trajectory with growth rates ranging from 24% to 37% over the past five quarters. This consistent increase reflects the rising importance of cybersecurity in today's digital landscape and CyberArk's ability to capitalize on this trend. Third is strategic

Acquisitions, the acquisition of Venafi, a leader in machine identity management, positions CyberArk to offer more comprehensive security solutions. This strategic move is expected to enhance the company's market position and drive future growth. Fourth is strong analyst support. CyberArk has received a consensus

rating of moderate buy from analysts with an average price target of $342. This indicates confidence in the company's future prospects and suggests potential upside from current levels. Fifth is market leadership in privileged access management. As a leader in privileged access management, CyberArk serves high-profile clients

like Cisco and Capcom. This leadership position provides a competitive edge and a solid foundation for sustained growth. In summary, CyberArk's impressive earnings, revenue growth, strategic acquisitions, analyst support, and market leadership make it a compelling investment. However, as always, it's crucial to conduct your own research and

consider your investment objectives before making any decisions. The last stock Greg is pitching is a biotech company that specializes in gene editing. This stock is CRISPR Therapeutics and the ticker is CRSP. CRISPR Therapeutics is a biotechnology company specializing in the development of gene editing

therapies using CRISPR-Cas9 technology. Founded in 2013 by Emmanuelle Charpentier, Shaun Foy, and Rodger Novak, the company focuses on creating treatments for various diseases including blood disorders, cancer, diabetes, and other severe conditions. In December 2023,

CRISPR Therapeutics, in collaboration with Vertex Pharmaceuticals, received US Food and Drug Administration approval for CTX001, a gene therapy designed to treat sickle cell disease. This approval marked a significant milestone as CTX001 became the first CRISPR-based therapy to receive FDA approval. Since May 2024,

The stock has been very volatile and is essentially break even. Remember though, the market is up 18% in the same time period. I believe this stock is another borderline Buy, and here's why: First, it's pioneering gene editing technology. CRISPR Therapeutics is at the forefront

of gene editing innovation, utilizing the CRISPR-Cas9 platform to develop treatments for serious genetic diseases. Their lead product, Cas9, has received approval in Switzerland and Canada for treating sickle cell disease and transfusion-dependent beta thalassemia. Second is a robust pipeline with

diverse applications beyond Cas9. CRISPR Therapeutics is advancing a pipeline that includes CAR T-cell therapies targeting oncology and autoimmune diseases, in vivo gene editing for cardiovascular conditions, and stem cell-derived therapies for type 1 diabetes. This diversification positions

the company to address multiple high-need areas in medicine. Third is strategic collaborations enhancing development. The company has formed strategic partnerships with industry leaders like Vertex Pharmaceuticals, Viiv Healthcare, and Capsida Biotherapeutics. These collaborations leverage combined expertise and resources, except accelerating the

development and potential commercialization of innovative therapies. Fourth is a strong financial position with a market capitalization of approximately $4.09 billion and substantial cash reserves. CRISPR Therapeutics is well-equipped to fund ongoing research and development. This

financial stability supports the company's ability to advance its pipeline without immediate financial constraints. Fifth is analyst optimism and growth potential. Analysts have set a 12-month average price target of $73.69 for CRSP, indicating a potential upside of over 50% from its current price. This

reflects confidence in the company's growth prospects and the transformative potential of its therapies. In summary, CRISPR Therapeutics' leadership in gene editing technology, diverse therapeutic pipeline, strategic partnerships, solid financial foundation, and positive analyst outlook collectively suggest that the company is on the verge of

being a compelling investment opportunity. As always, it's crucial to conduct your own research and consider your investment objectives before making any decisions. And if you really want to make money with the stock market, make sure to click the link in the description to check out the Black Friday sale from

Seeking Alpha. This sale bundles Seeking Alpha with their market-beating stock picking service, Alpha Picks. Both of these are my favorite stock services, and if you buy between November 18th and December 5th, you can save nearly $300 by bundling the two.

offers. Take advantage of this deal, just click the link in the description and put yourself in the best position to succeed in investing.

Revealed: Alexander Green's "New  Magnificent Seven" Stocks (Turn $1,000 Into $1 Million?)

Hey!

I'm Dylan Rieger.. I help people create wealth online with passive income and investing. 

I like to review programs and make recommendations on which are worth your money.

I share stock insights as well.




Dylan Rieger

알렉산더 그린의 장엄한 7가지 주식 소개 및 개요

알렉산더 그린은 성장 잠재력이 높은 7가지 종목을 발굴했다고 주장합니다.

그는 이러한 주식을 공개하기 위해 뉴스레터를 홍보합니다.

발표자가 주식을 무료로 공개하고 좋아요와 구독을 요청합니다.

원래 프레젠테이션의 주식 두 개가 교체되었습니다.

개별 종목 분석: Arm 홀딩스 (ARMM), 클라우드플레어 (NET)

Arm 홀딩스 (ARMM):  AIC CPU 개발사, 밸류에이션 우려, 스마트폰 시장 성장 둔화, 주요 고객에 대한 의존도, 경쟁, 지정학적 리스크 등을 분석하여 '보류'로 평가했습니다.

Cloudflare (NET): AI로 인터넷 재창조; 재무 성장, 전략적 포지셔닝, 고객 기반 확대, 시장 지위, 애널리스트 전망 등을 분석하여 '매수'로 평가했습니다.

개별 종목 분석: ASML (ASML), 팔란티르 (PLTR)

ASML (ASML): 엑손을 대체하는 신규 종목, EUV 기술 우위, 장기 성장 전망, AI 기반 수요, 재무 성과, 최근 주가 변동성 등을 분석하여 '경계선 매수'로 평가했습니다.

팔란티어 (PLTR): 신규 추가, 10배 지노믹스 대체; 높은 밸류에이션, 내부자 매도, 매출 성장 둔화, 애널리스트 회의론, 시장 변동성 등을 분석하여 '보류' 또는 '경계선 매도'로 평가했습니다.

개별 종목 분석: 심보틱 (SYM), 사이버아크 (CYBR)

심보틱(SYM): 창고 운영 자동화; 수익성 문제, 고객 집중 위험, 경쟁 환경, 구현 과제, 시장 변동성 등을 분석하여 '보류'로 평가했습니다.

CyberArk (CYBR): 신원 보안; 3분기 실적 호조, 매출 성장 가속화, 전략적 인수, 강력한 애널리스트 지원, 시장 리더십 등을 분석하여 '매수'로 평가했습니다.

개별 종목 분석: 크리스퍼 테라퓨틱스 (CRSP)

크리스퍼 테라퓨틱스(CRSP): 유전자 편집 치료제, 선구적인 기술, 강력한 파이프라인, 전략적 협업, 탄탄한 재무 상태, 애널리스트 낙관론 등을 분석하여 '경계선 매수'로 평가했습니다.

Revealed: Alexander Green's "New Magnificent Seven" Stocks (Turn $1,000 Into $1 Million?)

Revealed: Alexander Green's "New Magnificent Seven" Stocks (Turn $1,000 Into $1 Million?)

스크립트